MARY PINE: Open Payments
NPI 1649388588 · SUNNYSIDE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,064 in 48 payments from 13 companies in 2025. Trend: 2023 $817 · 2024 $820 · 2025 $1,064
Food & beverage: $1,064
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $313 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $157 |
| Lilly USA, LLC | 4 | $122 |
| Sumitomo Pharma America, Inc. | 4 | $101 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $80 |
| Novo Nordisk Inc | 3 | $67 |
| KYOWA KIRIN, INC. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| PFIZER INC. | 2 | $47 |
| Novartis Pharmaceuticals Corporation | 1 | $26 |
Products named: CAPLYTA, FARXIGA, MOUNJARO, GEMTESA, Kerendia, CRYSVITA, REXULTI, LEQVIO.
Industry payments across WA — which companies pay providers there.
